1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
169.30 USD   -7.54%
06:54aEU Health Agency Starts Real-time Review of Pfizer-BioNTech's Variant-specific COVID-19 Jab
MT
06:28aEU regulator begins review of Pfizer-BioNTech's variant-adapted COVID shot
RE
01:31aEXPLAINER-IN-BRIEF : More jabs on the horizon
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BioNTech Says 'Work is Original' Amid CureVac Lawsuit On mRNA-Related Patents Infringement

07/05/2022 | 11:34am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -7.54% 169.3 Delayed Quote.-28.97%
CUREVAC N.V. 1.16% 13.92 Delayed Quote.-59.43%
PFIZER, INC. 0.61% 49.57 Delayed Quote.-16.56%
All news about BIONTECH SE
06:54aEU Health Agency Starts Real-time Review of Pfizer-BioNTech's Variant-specific COVID-19..
MT
06:28aEU regulator begins review of Pfizer-BioNTech's variant-adapted COVID shot
RE
01:31aEXPLAINER-IN-BRIEF : More jabs on the horizon
AQ
01:31aBIONTECH posts €3.2bn second quarter revenue
AQ
08/08BioNTech, Pfizer could deliver Omicron-adapted COVID-19 vaccines in October
AQ
08/08SECTOR UPDATE : Health Care Stocks Getting Late Boost Back to Positive Ground
MT
08/08SECTOR UPDATE : Health Care Stocks Edging Lower This Afternoon
MT
08/08SECTOR UPDATE : Health Care
MT
08/08BioNTech Q2 Profit, Revenue Decline; Shares Drop
MT
08/08GLOBAL MARKETS LIVE : Tesla, Pfizer, CVS Health, Amazon, Credit Suisse...
MS
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2022 16 911 M 17 283 M 17 283 M
Net income 2022 8 790 M 8 983 M 8 983 M
Net cash 2022 9 786 M 10 001 M 10 001 M
P/E ratio 2022 4,91x
Yield 2022 -
Capitalization 40 259 M 41 143 M 41 143 M
EV / Sales 2022 1,80x
EV / Sales 2023 1,51x
Nbr of Employees 3 082
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 165,66 €
Average target price 227,16 €
Spread / Average Target 37,1%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-28.97%41 143
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%75 386
REGENERON PHARMACEUTICALS, INC.-2.84%67 420
WUXI APPTEC CO., LTD.-20.64%40 375
GENMAB A/S-2.51%22 993